Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression

Laboratory Investigation

Volumn 78, Issue 5, 1998, Pages 541-550

  Wagner, Stephan N ^a   Schultewolter, Thomas ^b   Wagner, Christine ^b   Briedigkeit, Lutz ^b   Becker, Jürgen C ^b   Kwasnicka, Hans M ^b   Goos, Manfred ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN METASTASIS; TUMOR IMMUNITY;

ANTIBODIES; ANTIBODY FORMATION; CELL MOVEMENT; CYTOKINES; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; LYMPHOCYTES; MELANOMA; REMISSION, SPONTANEOUS; RNA, MESSENGER; SKIN NEOPLASMS;

EID: 0031835341     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Müller U, and Blaser K (1996). Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL2 and IL15 in vitro. J Clin Invest 98:1676-1683.
2. Azzarone B, Pottin-Clemenceau C, Krief P, Rubinstein E, Jasmin C, Scudeletti M, and Indiveri F (1996). Are interleukin-2 and interleukin-15 tumor promoting factors for non-hematopoietic cells? Eur Cytokine Netw 7:27-36.
3. Barth RJ, Mule JJ, Spiess PJ, and Rosenberg SA (1991). Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor infiltrating lymphocytes. J Exp Med 173:647-658.
4. Baskar S (1996). Gene-modified tumor cells as cellular vaccine. Cancer Immunol Immunother 43:165-173.
5. Brandes ME, Wakefield LM, and Wahl SM (1991). Modulation of monocyte type I transforming growth factor-beta receptors by inflammatory stimuli. J Biol Chem 266:19697-19703.
6. Cameron RB, Spiess PJ, and Rosenberg SA (1990). Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin-2, and local irradiation: Studies on the mechanism of action. J Exp Med 171:249-263.
7. Chen W and Zlotnik A (1991). IL-10: A novel cytotoxic T cell differentiation factor. J Immunol 147:528-534.
8. Colombo MP, Maccalli C, Mattei S, Melani S, Radrizzani M, and Parmiani G (1992). Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T lymphocyte cross-talk. Cancer Res 52:4853-4857.
9. Darrow TL, Slingluff CL, and Seigler HF (1988). Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. Cancer 62:84-91.
10. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, and Frost P (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403.
11. Gamero AM, Ussery D, Reintgen DS, Puleo CA, and Djeu JY (1995). Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-independent, perforinrelated mechanism. Cancer Res 55:4988-4994.
12. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn RA, Ahdieh M, Johnson L, Alderson MR, Watson JD, Anderson DM, and Giri JG (1994). Cloning of a T cell growth factor that interacts with the β-chain of the interleukin-2 receptor. Science 264:965-968.
13. Guilloux Y, Viret C, Gervois N, Le Drean E, Pandolfino MC, Diez E, and Jotereau F (1994). Defective lymphokine production by most CD8+ and CD4+ tumor specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Eur J Immunol 24:1966-1973.
14. Haraguchi S, Good RA, James-Yarish M, Cianciolo GJ, and Day NK (1995). Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein. Proc Natl Acad Sci USA 92:3611-3615.
15. Heinzel FP, Sadick MD, Holadday BJ, Coffman RL, and Locksley RM (1989). Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis: Evidence for expansion of distinct helper T-cell subsets. J Exp Med 169:59-72.
16. Hérin M, Lemoine C, Weynants P, Vessière F, van Pel A, Knuth A, Devos R, and Boon T (1987). Production of stable cytolytic T cell clones directed against autologous human melanoma. Int J Cancer 39:390-396.
17. + T lymphocyte migration. J Immunol 152:4545-4551.
18. Kanegane H and Tosato G (1996). Activation of naive and memory T cells by interleukin-15. Blood 88:230-235.
19. Keller G, Kennedy M, Papayannopoulou T, and Wiles MV (1993). Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol Cell Biol 13:473-486.
20. Leclercq G, Debacker V, de-Smedt M, and Plum J (1996). Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/NK killer progenitor cells. J Exp Med 184:325-336.
21. Lüscher U, Filgueira L, Juretic A, Zuber M, Lüscher NJ, Heberer M, and Spagnoli GC (1994). The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 57:612-619.
22. Marincola FM, Ettinghausen S, Cohen PA, Cheshire LB, Restifo NP, Mule JJ, and Rosenberg SA (1994). Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. J Immunol 152:3500-3513.
23. McGovern VJ (1975). Spontaneous regression in melanoma. Pathology 7:91-99.
24. Meazza R, Verdiani S, Biassoni R, Coppolecchia M, Gaggero A, Orengo AM, Colombo MP, Azzarone B, and Ferrini S (1996). Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene 12:2187-2192.
25. Musiani P, Modesti A, Giovarelli M, Cavallo F, Colombo MP, Lollini PL, and Forni G (1997). Cytokines, tumour-cell death and immunogenicity: A question of choice. Immunol Today 18:32-36.
26. Muul LM, Spiess PJ, Director EP, and Rosenberg SA (1987). Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989-995.
27. Onu A, Pohl T, Krause H, and Bulfone-Paus S (1997). Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J Immunol 158:255-262.
28. Pardoll DM (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399-415.
29. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, and Kehrl JH (1986). Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167-4171.
30. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber DJ, Wei JP, and White DE (1988). Use of tumor infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma: A preliminary report. N Engl J Med 319:1676-1680.
31. Rosenberg SA, Spiess P, and Lafreniere R (1986). A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233:1318-1321.
32. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JA, and White DE (1994a). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913.
33. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, and White DE (1994b). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166.
34. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, and Pfreundschuh M (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810-11813.
35. Schwarz MA, Hamilton LD, Tardelli L, Narula SK, and Sullivan LM (1994). Stimulation of cytolytic activity by IL-10. J Immunother 16:95-104.
36. Smith JLJ and Stehlin JSJ (1965). Spontaneous regression of primary malignant melanoma with regional metastases. Cancer 18:1399-1405.
37. Swain SL, Huston S, Tonkonogy S, and Weinberg A (1991). Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 147:2991-3000.
38. Taniguchi T and Minami Y (1993). The IL2/IL2-receptor system: A current overview. Cell 73:5-8.
39. thor Straten P, Becker JC, Seremet T, Bröcker EB, and Zeuthen J (1996). Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest 98:279-284.
40. Wagner SN, Wagner C, Höfler H, Atkinson MJ, and Goos M (1995). Expression cloning of the cDNA encoding a melanoma-associated antigen recognized by monoclonal antibody HMB-45: Identification as melanocyte-specific Pmel 17 cDNA. Lab Invest 73:229-235.
41. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, and Modlin RL (1991). Defining protective response to pathogens: Cytokine profiles in leprosy lesions. Science 254:277-279.